The U.S. Health Resources and Services Administration (HRSA) yesterday asked the White House for permission to rescind the Trump administration’s final rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the price the centers pay for those drugs under the 340B program.
HRSA sent its proposal to rescind the 340B health center insulin pricing rule to the Office of Management and Budget for review and approval yesterday.
The U.S. Health Resources and Services Administration (HRSA) yesterday asked the White House for permission to rescind the Trump administration’s final rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the price the centers pay for those drugs under the 340B program.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
